Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingUniveraHealthcare Prostate MRI Coverage Update | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifieduniverahealthcarePolicy 6.01.46

    Magnetic Resonance Imaging (MRI) of the Prostate

    Customize your policy alerts

    Sign up for univerahealthcare Policy 6.01.46 alerts

    Get alerted when Policy 6.01.46 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical criteria for when pelvic MRI (with or without contrast) of the prostate is considered medically appropriate for men with suspected prostate cancer; intended for providers and authorization staff.

    Policy Summary
    Payeruniverahealthcare
    PolicyMagnetic Resonance Imaging (MRI) of the Prostate
    Policy CodePolicy 6.01.46
    Change TypeAdded/Removed/Revised clinical criteria
    Effective DateOct 15, 2026
    Last ReviewJun 18, 2026
    Next Review DateJun 1, 2027
    Key ActionObtain prior authorization documenting the clinical criteria (age, PSA/DRE, and qualifying high‑risk features) before scheduling prostate MRI.
    SourceLink
    POLICY UPDATE CHANGES

    New criteria for suspected prostate cancer were added, restaging criteria added and removed criteria for non-metastatic prostate cancer previously treated with prostatectomy, radiation therapy, ablation hormonal therapy or chemotherapy regarding PSA fails to fall post prostatectomy.

    Criteria regarding salvage local therapy was removed.

    Previously allowed indications for patients with PI-RADS 4 or 5 lesions were modified and now only allows for solitary PIN lesions.

    A new not medically necessary policy statement for serial MRIs was added.

    Codes 76376, 76377 and 76942 were removed due to being unmanaged.

    40-75Age range (PSA >3 or very suspicious DRE + high-risk)
    ≥4PSA threshold for >75 yrs
    1 yrSolitary PIN repeat interval
    mpMRIPreferred staging modality
    Not coveredMR guidance for needle placement
    3 codesProcedure codes listed

    Coverage Criteria — When MRI of the Prostate is Medically Appropriate

    Suspected Prostate Cancer — age 40-75 with high-risk features

    Covered when ALL of the following are met:

    Age and screening thresholds: Patient is 40 to 75 years old with PSA > 3 ng/ml or very suspicious digital rectal exam (DRE)PSA > 3 ng/ml
    High-risk features (one required): One of: Black/African American ancestry; germline mutations that increase the risk of prostate cancer; family history of first- or second-degree relative with prostate, male breast, pancreatic, or ovarian cancer; family history of two or more first-degree relatives diagnosed at any age with colorectal, endometrial, breast, or prostate cancer; first- or second-degree relative diagnosed ≤45 years with female breast cancer; first- or second-degree relative diagnosed ≤50 years with colorectal or endometrial cancer; family history of pancreatic cancer

    High-risk feature list from policy

    Suspected Prostate Cancer — age 45-75

    Covered when ANY of the following are met:

    Policy Summary
    Payeruniverahealthcare
    PolicyMagnetic Resonance Imaging (MRI) of the Prostate
    Policy CodePolicy 6.01.46
    Change TypeAdded/Removed/Revised clinical criteria
    Effective DateOct 15, 2026
    Last ReviewJun 18, 2026
    Next Review DateJun 1, 2027
    Key ActionObtain prior authorization documenting the clinical criteria (age, PSA/DRE, and qualifying high‑risk features) before scheduling prostate MRI.
    SourceLink
    On This Page
    Coverage Criteria — When MRI of the Prostate is Medically AppropriateCovered Indications — Specific Uses Supported by This PolicyFrequency Limits and Repeat Interval GuidanceProcedure and Diagnosis CodesProvider Actions, Prior Authorization, and Documentation RequirementsUse of Contrast and mpMRI ComponentsServices and Uses Considered Not Medically NecessaryBackground and RationaleDefinitions and Key TermsPrior Authorization — When and How to Request ApprovalRevision History and Policy Changes
    Age 45-75 criteria: Patient is 45 to 75 years old, and ONE of the following: PSA > 3 ng/ml; or very suspicious DREPSA > 3 ng/ml

    Suspected Prostate Cancer — age >75

    Covered when ANY of the following are met:

    Age >75 criteria: Patient is greater than 75 years old, and ONE of the following: PSA ≥ 4 ng/ml; or very suspicious DREPSA ≥ 4 ng/ml

    Post-negative TRUS biopsy indications

    Covered when ALL of the following are met:

    Prior biopsy status: Patient has had at least one negative/non-diagnostic transrectal ultrasound (TRUS) biopsy
    Associated findings: And has any of: rising PSA; abnormal DRE; or need for confirmatory MR/US fusion biopsy

    Solitary PIN follow-up imaging

    Solitary PIN repeat MRI: Patient has a solitary (one) prostatic intraepithelial neoplasm (PIN) lesion; MRI Pelvis without contrast is appropriate to be repeated in one (1) yearrepeat in 1 year

    Follow-up for solitary prostatic intraepithelial neoplasm (PIN)

    Repeat imaging for solitary PIN lesion — any ONE of the following

    Repeat imaging options for solitary PIN: Any one of: MRI Pelvis without contrast; MRI Pelvis without and with contrast; or MRI/US fusion biopsyrepeat in 1 year

    Applies to a patient with a solitary (one) PIN lesion

    Initial Work-Up/Staging

    Initial work-up/staging for localized prostate cancer — MRI Pelvis without and with contrast is appropriate when ANY of the following risk groups/conditions apply

    Risk groups: Any of: Low risk; Favorable intermediate risk; Unfavorable intermediate risk; High-risk; Very high-riskN/A

    Refer to Policy Guideline for NCCN Initial Risk Stratification

    Favorable intermediate risk indications: For favorable intermediate risk: either to establish candidacy for active surveillance OR prior to planned treatment (surgery and/or radiation therapy)N/A

    Either indication is sufficient

    Very High-Risk Staging Imaging Combinations

    For very high-risk patients, additional imaging combinations may be obtained in addition to mpMRI:

    Very high-risk additional imaging options: Any one of (may be obtained in addition to mpMRI): (1) CT Chest with contrast + CT Abdomen and Pelvis with contrast + Bone scan; (2) CT Chest with contrast + CT Abdomen with contrast + MRI Pelvis without and with contrast (if not previously performed) + Bone scan; (3) PSMA PET/CT using appropriate radiotracersN/A

    These combinations are additional to mpMRI prostate

    Restaging/Recurrence

    Restaging/Recurrence — MRI of the prostate without and with contrast is appropriate for patients with any of the following:

    Restaging/recurrence indications: Any of: obvious progression by DRE with plans for prostatectomy or radiation therapy; repeat TRUS biopsy for rising PSA showing progression to a higher Gleason score with plans for prostatectomy or radiation therapy; inconclusive findings on CT scanN/A

    Any one of these triggers appropriateness for MRI pelvis with and without contrast

    Restaging/Recurrence - general indications

    MRI of the prostate without and with contrast is considered medically appropriate for restaging or recurrence when ANY of the following are present:

    Repeat TRUS biopsy showing Gleason progression: Repeat TRUS biopsy for rising PSA shows progression to a higher Gleason score, with plans for prostatectomy or radiation therapy
    Inconclusive CT findings: Inconclusive findings on CT scan
    Non-metastatic treated disease with signs/symptoms: Non-metastatic prostate cancer treated with prostatectomy or radiation therapy that do not meet criteria for PSMA PET/CT but have clinical signs/symptoms of recurrence

    Restaging/Recurrence - detailed post-treatment criteria

    Non-metastatic prostate cancer previously treated (prostatectomy, radiation, ablation, hormonal therapy, or chemotherapy): MRI is appropriate when ANY ONE of the following is met and additional specified conditions are present:

    Post-treatment clinical triggers: Clinical suspicion of relapse/recurrence
    Palpable anastomotic recurrence
    PSA >0.2 ng/ml on two measurements pathway: PSA rises above post-treatment baseline to >0.2 ng/ml on two (2) consecutive measurements; AND any ONE of the following imaging combinations: (1) CT Chest with contrast + CT Abdomen and Pelvis with contrast + Bone scan; OR (2) CT Chest with contrast + CT Abdomen with contrast + MRI Pelvis without and with contrast + Bone scanPSA >0.2 ng/ml x2
    Persistent detectable PSA after prostatectomy
    Undetectable then detectable PSA: Undetectable PSA that subsequently becomes detectable with two (2) consecutive increases in PSA (to any amount)two consecutive increases
    Any increase to >=0.1 ng/ml pathway: Any increase in PSA to 0.1 ng/ml or higher; AND any ONE of the following imaging options: (1) CT Chest with contrast + CT Abdomen and Pelvis with contrast + Bone scan; OR (2) CT Chest with contrast + CT Abdomen with contrast + MRI Pelvis without and with contrast + Bone scan; OR (3) PSMA PET/CT using appropriate radiotracersPSA >=0.1 ng/ml
    Post-radiation recurrence: Non-metastatic prostate cancer previously treated with radiation therapy and two (2) consecutive increases in PSA above nadir (lowest point)two consecutive increases above nadir

    Active Surveillance follow-up

    MRI Pelvis without or without and with contrast is considered medically appropriate for follow-up on active surveillance when ANY of the following are present:

    Routine active surveillance monitoring: Use for routine monitoring of individuals on an active surveillance protocol
    Suspected progression with negative recent TRUS: Progression is suspected based on DRE changes or rising PSA and a recent TRUS biopsy was negative
    TRUS biopsy shows Gleason progression: Repeat TRUS biopsy shows progression to a higher Gleason score

    Active Surveillance and Diagnostic Use

    Covered when following surveillance and diagnostic principles are met:

    Active surveillance monitoring schedule: Patients on active surveillance per NCCN should have PSA every 6 months; DRE every 12 months; repeat TRUS-guided prostate biopsy every 12 months; and repeat mpMRI no more often than every 12 months unless clinically indicated.mpMRI no more often than every 12 months

    mpMRI interval may be shortened if clinically indicated.

    mpMRI as diagnostic triage: mpMRI may be used as a gatekeeper/triage test prior to biopsy with lesions assigned PI-RADS 1-5 to indicate likelihood of clinically significant prostate cancer; use of mpMRI can reduce number of TRUS biopsies.PI-RADS scoring

    Evidence supports targeted biopsy when mpMRI is suggestive; systematic biopsy may still detect some csPCa.

    Indications for mpMRI prior to biopsy

    Coverage and use supported when consistent with guideline-recommended indications and study evidence

    Pre-biopsy mpMRI: mpMRI performed prior to initial prostate biopsy to risk-stratify patients and guide targeted biopsy, consistent with guideline recommendations (NCCN/AUA/NICE)PI-RADS/Likert reporting preferred

    Supported by randomized trials and meta-analyses showing reduced unnecessary biopsies and maintained detection of clinically significant prostate cancer.

    MRI-targeted biopsy vs systematic biopsy

    Use of MRI-targeted and systematic biopsy approaches

    Biopsy strategies: MRI-targeted biopsy with or without concurrent systematic biopsy when mpMRI identifies suspicious lesions; in biopsy-naive patients, targeted biopsy may be used and is noninferior to standard TRUS-guided biopsyPI-RADS >=3 or Likert >=3 commonly used thresholds in studies

    Some studies show combining targeted and systematic biopsy increases detection; omission of systematic biopsy may miss a minority of csPCa.

    Staging, recurrence, and active surveillance

    Staging and surveillance uses

    Staging and recurrence evaluation: mpMRI can be used for initial risk stratification, local staging, and evaluation after treatment when PSA rises or for consideration of local salvage therapy; repeat mpMRI generally no more often than every 12 months unless clinically indicated.repeat mpMRI >= 12 months unless clinically indicated

    Guidelines recommend mpMRI as part of staging for high-risk localized prostate cancer and in active surveillance to augment but not replace periodic biopsy.

    Recent Criteria Revisions

    Summary of recent criteria changes and scope adjustments

    Recent changes: New criteria for suspected prostate cancer were added; restaging criteria were added; and criteria for non-metastatic prostate cancer previously treated regarding PSA fails to fall post-prostatectomy were removed.

    See policy history entries for dates

    PI-RADS indication change: Previously allowed indications for patients with PI-RADS 4 or 5 lesions were modified; policy now allows only solitary PIN lesions under a specified statement.

    Recorded in policy history.

    Serial MRI statement: A new not medically necessary policy statement for serial MRIs was added.

    Recorded 06/26/25 in policy history.

    This policy defines the clinical situations in which MRI of the prostate (pelvis MRI with or without contrast) is considered medically appropriate. Covered indications include age- and PSA/DRE–based evaluations for suspected prostate cancer, post-negative transrectal ultrasound (TRUS) biopsy workup, follow-up of a solitary prostatic intraepithelial neoplasm (PIN) lesion, initial staging across NCCN risk groups, restaging and evaluation for suspected recurrence, and active surveillance when specified criteria are met. Prior authorization and documentation must demonstrate the applicable clinical criteria (age, recent PSA, DRE findings, prior biopsy results, and any high-risk features) are present to support medical necessity.

    MR guidance for needle placement for prostate biopsy is not medically necessary. Requests coded as MRI guidance for needle placement (MR-guided needle placement) for prostate biopsy should be considered not medically necessary and may be denied.

    Serial MRIs to monitor an elevated PSA alone are not medically necessary. Repeated MRI examinations performed solely for surveillance of an elevated prostate-specific antigen (PSA) without meeting other defined clinical criteria are considered not medically necessary.

    Monitoring an elevated PSA with serial MRI is specifically not indicated for suspected prostate cancer. Requests for serial MRI examinations based only on an elevated PSA value, without meeting the policy’s covered indications, do not meet medical necessity criteria.

    Do not routinely offer multiparametric MRI (mpMRI) to individuals with prostate cancer who are not candidates for radical treatment. The NICE guideline recommendation cited in this policy advises against routine mpMRI in patients who will not undergo radical therapy.

    Policy history documents that indications related to PI-RADS 4 or 5 lesions were revised and that a new not medically necessary statement for serial MRIs was added (off-cycle update 06/26/25). This update explicitly added serial MRI surveillance to the list of not medically necessary indications.

    Clinical requests for prostate MRI must include sufficient documentation to demonstrate the applicable coverage criteria are met. Key documentation elements include patient age, a recent PSA value, DRE findings, prior TRUS biopsy results when applicable, and any specified high-risk features used to determine eligibility for imaging.

    Reiterating the exclusion: MR guidance for needle placement for prostate biopsy is explicitly considered not medically necessary. When MR guidance for needle placement is billed or requested, the policy position supports denial unless other covered indications apply and the service is billed under an appropriate, covered code.

    Restating the policy: Serial MRI monitoring for an elevated PSA alone (without meeting other listed clinical criteria) is not medically necessary. Imaging requests for serial MRIs should be accompanied by qualifying clinical triggers defined in the policy to be considered for coverage.

    Routine use of mpMRI is not recommended for patients who are not candidates for radical treatment; mpMRI should be reserved for situations where the results would affect clinical management, consistent with guideline recommendations.

    Policy-history note: an off-cycle revision documented that a not medically necessary statement for serial MRIs was added and that prior indications related to PI-RADS 4 or 5 were narrowed to allow only for solitary PIN lesion follow-up under specified conditions.

    Covered Indications — Specific Uses Supported by This Policy

    Suspected prostate cancer or follow-up of specific prostate pathology (PIN) per age and clinical criteria

    Top-level: Suspected prostate cancer or follow-up of specific prostate pathology (PIN) per age and clinical criteria as specified in the age-based and PIN sections of the policySee respective criteria

    Top-level grouping of age-based suspected cancer and solitary PIN follow-up indications

    Initial work-up/staging of localized prostate cancer

    Initial work-up/staging indications: MRI Pelvis without and with contrast for initial workup or staging of localized prostate cancer for any of the NCCN-defined risk groups (low; favorable intermediate; unfavorable intermediate; high; very high).N/A

    Refer to Policy Guideline for NCCN initial risk stratification; favorable intermediate risk may be for active surveillance candidacy or prior to planned treatment

    Restaging or evaluation of suspected recurrence

    Restaging/recurrence indications: MRI Pelvis without and with contrast for evaluation of suspected recurrence or restaging when there is obvious progression by DRE, repeat TRUS biopsy with rising PSA showing higher Gleason, or inconclusive CT findingsN/A

    Any one of these is sufficient

    Follow-up imaging for solitary PIN lesion

    Solitary PIN follow-up: Patient with a solitary (one) prostatic intraepithelial neoplasm (PIN) — any one of MRI Pelvis without contrast; MRI Pelvis without and with contrast; or MRI/US fusion biopsy is appropriate to be repeated in one yearrepeat in 1 year

    Any one option appropriate

    Appropriate use indications for prostate MRI

    Appropriate use indications include restaging/recurrence triggers, PSA-based recurrence thresholds, and active surveillance follow-up criteria as specified in the policySee detailed criteria

    Pre-biopsy diagnostic imaging to detect clinically significant prostate cancer and guide targeted biopsy

    Pre-biopsy diagnostic imaging: Pre-biopsy mpMRI to detect clinically significant prostate cancer and guide targeted biopsy; use PI-RADS/Likert reporting and consider mpMRI as gatekeeper prior to TRUS biopsyPI-RADS thresholds referenced

    Supported by randomized trials and meta-analyses

    Appropriate clinical indications for prostate MRI

    Staging, recurrence, surveillance, and pre-biopsy uses: Appropriate clinical indications include: staging/initial risk stratification, evaluation for recurrence/restaging, active surveillance monitoring, and pre-biopsy diagnostic imaging consistent with guideline recommendations.See policy details

    PI-RADS/Likert reporting and guideline alignment referenced

    Suspected prostate cancer / restaging

    Combined suspected prostate cancer / restaging node: Recent policy updates added new criteria for suspected prostate cancer and restaging, revised PI-RADS-related indications to now only allow solitary PIN imaging in that context, and added a not medically necessary statement for serial MRIs.

    See policy history for dates and details

    Solitary PIN — definition and 1‑year repeat recommendation
    DefinitionSolitary PIN = a single (one) prostatic intraepithelial neoplasm lesion noted on prior evaluation.
    Recommended follow-up intervalRepeat MRI pelvis (see options) may be performed in one (1) year following identification of a solitary PIN lesion.
    Permitted repeat modalitiesMRI Pelvis without contrast; MRI Pelvis without and with contrast; or MRI/US fusion biopsy (any one is appropriate at the 1-year repeat).

    Frequency Limits and Repeat Interval Guidance

    MRI — Repeat MRI pelvis without contrast in one year (solitary PIN guidance)
    ScopeRepeat MRI pelvis without contrast may be performed for a patient with a solitary PIN lesion as an appropriate follow-up imaging option.
    TimingRepeat imaging indicated at one (1) year after initial identification of solitary PIN.
    Contrast usePolicy lists MRI Pelvis without contrast as an acceptable repeat modality (alternatively MRI without and with contrast is also allowed).
    MRI pelvis or MRI/US fusion biopsy — repeat in 1 year
    Allowed optionsFor solitary PIN follow-up, repeat MRI Pelvis without and with contrast OR MRI/US fusion biopsy are appropriate options to repeat at one year.
    IntervalRepeat interval specified as one (1) year.
    Choice of modalityAny one of the listed modalities (MRI without and with contrast or MRI/US fusion biopsy) may be used based on clinical context and provider preference.
    MRI — no more often than every 12 months (active surveillance repeat interval)
    Active surveillance intervalRepeat mpMRI should be performed no more often than every 12 months for patients on active surveillance (unless clinically indicated).
    ContextThis interval is a key principle of NCCN-based active surveillance guidance referenced in the policy.
    ExceptionInterval may be shortened if there is a new clinical indication or change in status (i.e., clinically indicated).
    MRI — Repeat mpMRI no more often than every 12 months unless clinically indicated (NCCN‑aligned)
    Frequency limit (NCCN-aligned)Repeat mpMRI no more often than every 12 months unless clinically indicated; this aligns with NCCN/AUA guidance for surveillance intervals.
    Use caseApplies to patients on active surveillance and to staging/surveillance pathways where repeat mpMRI is used as part of monitoring.
    Clinical exceptionShortening of interval permitted when new clinical findings (rising PSA, abnormal DRE, or other indications) justify earlier imaging.
    MRI — frequency limits (summary of solitary PIN & surveillance rules)
    Solitary PIN repeatRepeat imaging for solitary PIN is specified at one (1) year and may use MRI without contrast, MRI without and with contrast, or MRI/US fusion biopsy.
    Active surveillance frequencyRepeat mpMRI generally no more often than every 12 months (unless clinically indicated).
    Clinical justificationAny deviation from stated frequency limits should be supported by clinical indications such as rising PSA or new exam findings.

    Procedure and Diagnosis Codes

    Covered CPT CodesCPTCovered
    72195Magnetic resonance (e.g., proton) imaging, pelvis; without contrast material(s).
    72197Magnetic resonance (e.g., proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences.
    77021Magnetic resonance imaging guidance for needle placement (e.g., for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation
    Relevant ICD-10 CodesICD-10
    C61Malignant neoplasm of prostate.
    D07.5Carcinoma in situ of prostate.
    D29.1Benign neoplasm of prostate.
    D40.0Neoplasm of uncertain behavior of prostate.
    N40.2Nodular prostate without lower urinary tract symptoms.
    N40.3Nodular prostate with lower urinary tract symptoms.
    N42.30Unspecified dysplasia of prostate.
    N42.31Prostatic intraepithelial neoplasia.
    N42.32Atypical small acinar proliferation of prostate.
    N42.39Other dysplasia of prostate.
    1–10 of 14
    1/2
    Removed/Unmanaged CodesCPTNot Covered
    76376Unmanaged/removed code
    76377Unmanaged/removed code
    76942Unmanaged/removed code
    PSA thresholds by age — age‑specific PSA triggers
    Age 40–75 thresholdPatients 40 to 75 years: PSA greater than 3 ng/mL (or very suspicious DRE with high‑risk features) triggers consideration for MRI.
    Age 45–75 thresholdPatients 45 to 75 years: PSA greater than 3 ng/mL (or very suspicious DRE) is an indication for MRI.
    Age >75 thresholdPatients greater than 75 years: PSA greater than or equal to 4 ng/mL (or very suspicious DRE) is an indication for MRI.
    PSA thresholds — biochemical recurrence triggers
    Biochemical recurrence — two consecutive measuresPSA rises above post‑treatment baseline to greater than 0.2 ng/mL on two (2) consecutive measurements is a trigger for MRI in restaging pathways.
    Undetectable then detectableAn undetectable PSA that subsequently becomes detectable with two (2) consecutive increases (to any amount) is an indication for imaging.
    Any increase ≥0.1 ng/mL pathwayAny increase in PSA to 0.1 ng/mL or higher can trigger further imaging pathways when combined with specified imaging combinations.

    Provider Actions, Prior Authorization, and Documentation Requirements

    Prior Authorization

    Clinical-criteria-based prior authorization

    Prior authorization for pelvic MRI (with or without contrast) must document that the patient meets the policy clinical criteria (age, PSA/DRE thresholds and specified high‑risk features) because MRI pelvis is appropriate only when those criteria are met.

    • Use supporting clinical documentation to show the qualifying criterion (age, PSA, DRE, high‑risk features).
    Prior Authorization

    Prior authorization required for indicated MRI pelvis exams

    Prior authorization is required when requesting MRI pelvis (with or without contrast) for the listed indications, including initial staging, restaging/recurrence, post‑negative TRUS biopsy scenarios, and solitary PIN follow‑up.

    • Indications requiring authorization include solitary PIN repeat imaging, initial work‑up/staging across NCCN risk groups, and restaging/recurrence triggers.
    Denial Risk

    Serial MRI monitoring denied when based on PSA alone

    Serial MRI monitoring requested solely to monitor an elevated PSA is considered not medically necessary and will be denied; authorization must include other qualifying criteria if seeking repeat imaging.

    • Requests for serial MRI for PSA monitoring alone should not be authorized unless other policy indications are documented.
    Prior Authorization

    mpMRI frequency on active surveillance (authorization requirement)

    For patients on active surveillance, repeat mpMRI should be authorized only when documentation supports it and the interval should be no more often than every 12 months per NCCN unless there is a clinical indication to shorten the interval.

    • Include rationale in authorization if mpMRI is being requested sooner than 12 months (clinical indication required).
    Billing Rule

    Billing/coding: use listed CPTs; removed codes may trigger denial

    Claims and prior authorizations may be denied if billing codes do not match the CPT codes listed in the policy (72195, 72197, 77021) or if removed/unmanaged codes are used.

    • Avoid using codes 76376, 76377, and 76942 as these were removed/are unmanaged and may trigger denial.
    • Use 72195 or 72197 as appropriate for contrast use per the service performed.
    Prior Authorization

    Prior authorization dependent on product coverage

    If a Medicare product covers the MRI service and there is no national or local Medicare coverage decision, the medical policy criteria in this document apply; verify product coverage before authorization.

    • If a product does not cover the service, the medical policy criteria do not apply.
    Step Therapy

    Authorize MRI after negative/non‑diagnostic TRUS biopsy only with specified triggers

    If a prior TRUS biopsy was negative or non‑diagnostic, MRI (or MRI/US fusion biopsy) is appropriate only when associated with rising PSA, abnormal DRE, or the need for MR/US fusion biopsy—include those findings in the authorization documentation.

    • Document prior TRUS biopsy result and the associated trigger (rising PSA, abnormal DRE, or planned MR/US fusion biopsy).
    Prior Authorization

    Document imaging sequencing for very high‑risk staging

    For very high‑risk patients, MRI may be obtained in addition to or as part of combination staging studies (e.g., CT chest/abdomen/pelvis, bone scan, or PSMA PET/CT); authorization should document the planned imaging sequence.

    • Authorization should specify which combination is planned (CT chest + CT abdomen/pelvis + bone scan; CT chest + CT abdomen + MRI pelvis + bone scan; or PSMA PET/CT).
    Documentation Required

    Document imaging‑guided biopsy pathway and PI‑RADS findings

    Follow the MRI‑guided biopsy pathway documentation: if mpMRI is used to triage patients for targeted biopsy, include the PI‑RADS (or Likert) score and the planned targeted biopsy approach to support authorization.

    • Indicate whether a targeted biopsy only or targeted plus systematic biopsy is planned and include lesion PI‑RADS scores.
    Step Therapy

    No step therapy requirement described

    There are no step therapy requirements described in the policy; do not impose step therapy for MRI of the prostate beyond the stated clinical criteria.

    • Policy does not mandate a stepwise trial of other tests before MRI beyond meeting the listed clinical criteria.
    Documentation Required

    Required clinical documentation for authorization

    Requests must include required clinical documentation: patient age, a recent PSA value, DRE findings, presence of specified high‑risk features, and prior TRUS biopsy results when applicable to support the requested imaging.

    • For staging or restaging include NCCN risk stratification details and relevant prior treatments/imaging.
    • For PSA‑based requests include the most recent PSA value and timing.
    Documentation Required

    Supportive clinical documentation required for staging MRI

    Provide supportive documentation for staging MRI that demonstrates NCCN initial risk stratification (low, favorable/unfavorable intermediate, high, very high) and the rationale for MRI as part of the staging workup.

    • Include the specific risk group and whether MRI is requested to establish active surveillance candidacy or prior to planned treatment.
    • For very high‑risk patients, document the intended additional imaging (CT, bone scan, PSMA PET/CT) if applicable.
    Documentation Required

    Support post‑treatment PSA documentation for staging MRI

    Documentation supporting staging MRI should include PSA values and timing consistent with recurrence criteria (for example, PSA >0.2 ng/mL on two consecutive measurements) when post‑treatment evaluation is the indication.

    • When applicable, include prior imaging and treatments (prostatectomy, radiation, ablation, systemic therapy) in the submission.
    Documentation Required

    Include recent PSA value with PSA‑based imaging requests

    Include in authorization requests a recent PSA value when the imaging is being requested on the basis of PSA; lack of a recent PSA is a documentation deficiency and may lead to denial.

    • Attach the most recent PSA and date to the prior authorization submission.
    Note
    Note

    Product coverage verification required

    Verify product coverage before initiating prior authorization because medical policy criteria apply only when the member's product covers the service.

    • If the product does not cover the service, do not submit authorization against this policy.
    Step Therapy

    Clinical step after negative TRUS biopsy — document triggers

    If a TRUS biopsy was negative or non‑diagnostic, MRI is appropriate when there is rising PSA, abnormal DRE, or need for MR/US fusion biopsy; include those clinical triggers in the authorization request.

    • Document prior biopsy date, result, and the clinical indication prompting MRI.
    Denial Risk

    MR guidance for needle placement is not covered (denial risk)

    When requesting MRI guidance for needle placement, be aware that MR guidance for needle placement is considered not medically necessary for prostate biopsy and such requests will be denied.

    • Do not submit requests or billing for MR guidance for needle placement to obtain prior authorization under this policy.
    Note
    Note
    Note
    Note
    Note

    Use of Contrast and mpMRI Components

    Billing Rule

    Contrast allowed for covered indications

    MRI pelvis may be performed with or without contrast; the policy does not restrict contrast use for covered indications.

    Billing Rule

    Indications determine contrast use

    MRI pelvis may be performed without contrast, or without and with contrast depending on indication; mpMRI includes both non-contrast and contrast components as appropriate for the clinical scenario.

    Billing Rule

    Permitted modality permutations for MRI pelvis

    Policy language specifies acceptable modality permutations (MRI pelvis without and with contrast; or MRI pelvis without contrast alone) and allows either approach for active surveillance as stated in the policy wording.

    Billing Rule

    mpMRI components include DCE

    Multiparametric MRI (mpMRI) includes dynamic contrast-enhanced (DCE) imaging as one of the component sequences along with T2 and diffusion-weighted imaging (DWI).

    Billing Rule

    Use CPT 72197 for without‑then‑with contrast MRI

    When contrast sequences are performed (without and then with contrast), use CPT 72197 to represent pelvic MRI performed without and then with contrast per the policy code table.

    Billing Rule

    mpMRI approaches referenced; no extra contrast rules

    The policy references multiparametric MRI approaches in the literature but does not specify additional administration rules for contrast beyond the indexed indications and coding guidance.

    Services and Uses Considered Not Medically Necessary

    Not covered summary: MR guidance for needle placement for prostate biopsy is not medically necessary, and serial MRI monitoring for an elevated PSA without meeting other defined criteria is not medically necessary. Additionally, routine mpMRI should not be offered to patients who are not candidates for radical treatment; these exclusions and revisions are reflected in the policy history.

    Not covered (duplicate): MR guidance for needle placement for prostate biopsy is explicitly not medically necessary. Serial MRI monitoring for an elevated PSA without other qualifying criteria is also considered not medically necessary and may be denied.

    Not covered (duplicate): The policy does not cover MR-guided needle placement for prostate biopsy and does not support serial MRI surveillance for an elevated PSA unless other policy-specified criteria are met.

    Routine mpMRI in patients who are not candidates for radical treatment is not recommended and should not be routinely offered; this aligns with the cited NICE guidance referenced in the policy.

    Not covered placeholder: services not listed in covered indications, or those lacking required documentation of qualifying clinical criteria, may be denied per this policy and product coverage rules.

    Background and Rationale

    Background: Multiparametric MRI (mpMRI) combines anatomical and functional MRI sequences—typically T2-weighted imaging, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) imaging—to detect and localize clinically significant prostate cancer and to guide targeted biopsy and risk stratification. mpMRI can reduce unnecessary systematic TRUS biopsies by identifying lesions that warrant targeted sampling, but it is used in conjunction with clinical assessment and, when indicated, biopsy.

    Definitions and Key Terms

    Solitary PIN — definition and MRI repeat statement
    DefinitionSolitary PIN = a single (one) prostatic intraepithelial neoplasm lesion identified on prior evaluation.
    Policy actionPolicy specifies that MRI may be repeated in one (1) year for a solitary PIN finding; permitted repeat modalities are listed in the policy.
    Permitted modalities at repeatMRI Pelvis without contrast; MRI Pelvis without and with contrast; or MRI/US fusion biopsy (any one appropriate at one year).
    Very suspicious DRE — definition used as a clinical trigger
    DefinitionVery suspicious DRE = digital rectal exam findings considered highly suspicious for prostate cancer and used as a clinical trigger alongside PSA thresholds in policy criteria.
    Role in criteriaVery suspicious DRE functions as an alternate trigger to PSA thresholds across age‑based indication sets (e.g., 40–75, 45–75, >75).
    DocumentationRequests based on DRE should include documentation of the abnormal/exam findings per the policy's required clinical documentation guidance.
    Solitary prostatic intraepithelial neoplasm (PIN) — repeat imaging options
    DefinitionSolitary prostatic intraepithelial neoplasm (PIN) = a single PIN lesion for which specified repeat imaging options are appropriate.
    Repeat imaging optionsAny one of: MRI Pelvis without contrast; MRI Pelvis without and with contrast; MRI/US fusion biopsy may be repeated at one (1) year.
    Indication contextApplied when a solitary PIN lesion was identified and follow‑up imaging is being considered.
    mpMRI prostate — definition (without and with contrast for initial workup/staging)
    DefinitionmpMRI prostate = magnetic resonance imaging of the pelvis/prostate obtained without and with contrast (multiparametric sequences) used for initial workup or staging.
    Typical componentsWhen described for staging, mpMRI is the pelvic MRI performed without and with contrast as noted in the initial workup/staging indications.
    Primary usesUsed for detection, local staging, risk stratification, and to guide targeted biopsy as part of initial workup/staging pathways.
    Biochemical recurrence triggers — PSA examples
    Examples of triggersPSA rises above post‑treatment baseline to >0.2 ng/mL on two consecutive measurements; undetectable PSA that becomes detectable with two consecutive increases; any increase to ≥0.1 ng/mL.
    Use in restagingThese PSA‑based biochemical recurrence triggers are used to determine appropriateness of MRI pelvis without and with contrast in restaging pathways.
    Documentation requirementRequests should include PSA values and timing to support imaging requests per policy documentation guidance.
    mpMRI components — T2, DWI, DCE sequences
    Component sequencesmpMRI consists of three imaging pulse sequences: T2‑weighted imaging, diffusion‑weighted imaging (DWI), and dynamic contrast‑enhanced imaging (DCE).
    Purpose of sequencesThese sequences combine anatomic and functional information to assign PI‑RADS scores and detect clinically significant prostate cancer.
    Reporting implicationUse of these component sequences supports standardized reporting (PI‑RADS) referenced in the policy literature and guidance.
    ISUP Grade Groups — grading referenced
    DefinitionISUP Grade Groups = International Society of Urological Pathology prostate cancer Grade Groups (2019) mapping Gleason patterns to Grade Groups for risk stratification.
    UseGrade Groups are used to categorize prostate cancer aggressiveness (e.g., Grade Group 2 and higher often considered clinically significant).
    Reference yearPolicy references the 2019 ISUP Grade Group consensus for grading definitions used in literature citations.
    Clinically significant prostate cancer (csPCa) — general definition
    csPCa definitionClinically significant prostate cancer (csPCa) generally refers to cancers of ISUP/Grade Group 2 or higher, as used in the policy and cited studies.
    ContextDetection of csPCa is a primary outcome in the supportive literature evaluating mpMRI pathways.
    Implication for biopsympMRI findings and PI‑RADS scoring are used to select patients for targeted biopsy to detect csPCa (Grade Group ≥2).
    mpMRI definition (duplicate) — sequences and purpose
    Definition duplicateMultiparametric MRI (mpMRI) = MRI technique incorporating multiple sequences (T2, DWI, DCE) to identify suspicious lesions and guide biopsy and staging.
    Sequences listedT2‑weighted imaging, diffusion‑weighted imaging (DWI), and dynamic contrast‑enhanced imaging (DCE) are the constituent sequences.
    Clinical rolesUsed for diagnosis, pretreatment risk assessment, staging, active surveillance monitoring, and to target biopsies.
    Multiparametric MRI — technique description (T2, DWI, DCE)
    Technique descriptionMultiparametric MRI uses T2, diffusion‑weighted imaging (DWI), and dynamic contrast‑enhanced imaging (DCE) to form anatomic and functional images for detection and risk assessment of prostate cancer.
    Clinical utilityCombining these sequences allows PI‑RADS scoring to indicate likelihood of clinically significant cancer and to guide targeted biopsy.
    Policy linkageThe policy cites mpMRI technique details in the clinical background and supportive literature sections.
    PI‑RADS — referenced in policy history
    Reference to PI‑RADSPI‑RADS (Prostate Imaging Reporting and Data System) is referenced in the policy history regarding prior allowed indications for PI‑RADS 4 or 5 lesions and subsequent policy changes.
    Role in reportingPI‑RADS is used as a standardized lesion scoring system (scores 1–5) to communicate suspicion for clinically significant prostate cancer.
    Policy change notePolicy history documents modification of indications related to PI‑RADS 4 or 5 and the addition of solitary PIN‑specific language.

    Prior Authorization — When and How to Request Approval

    Prior Authorization

    Authorization requires meeting policy criteria

    Prior authorization must document that the policy clinical criteria are satisfied for the requested MRI pelvis (with or without contrast).

    Prior Authorization

    Authorization required for staging/restaging MRI

    Prior authorization is required for MRI pelvis when performed for the listed staging and restaging indications; include supportive clinical detail in the request.

    Prior Authorization

    Authorization must show criteria met; serial MRIs not covered

    Prior authorization must document that the policy criteria are met (e.g., PSA thresholds, active surveillance indications); serial MRIs requested for PSA monitoring alone are addressed as not medically necessary.

    Billing Rule

    Use listed CPT codes for authorization

    Use the policy-provided CPT codes (72195, 72197, 77021) for prior authorization submissions as applicable.

    Prior Authorization

    Subject to product coverage and Medicare determinations

    Medical policy criteria apply only when the member's product covers the service and when there are no Medicare national/local coverage decisions that supersede; verify product and Medicare determinations.

    Revision History and Policy Changes

    2026-06-18operational_revisionLatest

    Stratification category chart and new criteria for suspected prostate cancer were added; restaging criteria were added and criteria related to PSA failing to fall post-prostatectomy for non‑metastatic previously treated prostate cancer were removed; criteria regarding salvage local therapy were removed.

    2025-06-26off_cycle_revision

    Previously allowed indications for patients with PI-RADS 4 or 5 lesions were modified; policy now only allows solitary PIN lesions and a new not medically necessary policy statement for serial MRIs was added.

    2025-01-01administrative_update

    Summary of changes tracking was implemented.